AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02508480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Control
Description: The control SAU condition will be enhanced with a 60-minute peer-led manualized educational group session (Leaders' Guidelines and Handout for Participants are attached). It will provide participants with information about the nature of stigma and the laws in the U.S. that protect people with disabilities from discrimination. Participants will be engaged in a discussion about their use of different strategies for proactive coping with psychiatric stigma. This session will be co-led by the same peers who will be delivering the Photovoice program to the experimental group at relevant wave and study sites. Participants randomized to the enhanced Services as Usual control condition will be invited to join a Photovoice group once they complete the final 6-month follow-up assessment.
Study NCT03780764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A Pre-adjusted edgewise brackets: 3M Gemini Unitek, 0.022 Roth prescription brackets
Description: A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and tied with elastomers (figure of 8).
Study NCT03780764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self- ligating brackets: Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets
Description: Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and held in place by bracket's gate in the self-ligating brackets side.
Study NCT00077025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
Study NCT00077025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
Study NCT01840423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-104
Description: ODM-104
Study NCT01840423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01840423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entacapone
Description: entacapone + levodopa/carbidopa
Study NCT01840423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: entacapone + levodopa/carbidopa
Study NCT03570294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atosiban
Description: The initial dose of Atosiban (Tractocile, Ferring Pharmaceuticals A/S, Copenhagen, Denmark) will be give as a single intravenous bolus dose (6.75 mg in 0.9 ml isotonic sodium chloride solution). This will be follow immediately by intravenous infusion of 300 μg/min of Atosiban in 5% glucose for 3 hours, and then 100 μg/min for up to 48 hours. Venous blood samples from a forearm vein will take before and after 48 hours of continuous administration tocolytic therapy with Atosiban.
Study NCT02999776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser microporation alone
Description: The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
Study NCT02999776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care-daily administration of Daivobet
Description: The other control treatment is Daivobet®, which is applied topically daily for 8 weeks on one pre-selected randomized plaque.
Study NCT02999776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laser microporation + topical application of Etanercept
Description: Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
Study NCT03305016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon hGH
Description: Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week
Study NCT02205710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Study NCT02205710 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Computerized games
Study NCT03667053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasiglucagon
Description: glucagon analog
Study NCT03667053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for dasiglucagon
Study NCT03667053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GlucaGen HypoKit
Description: native glucagon
Study NCT02700282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Backpack Carrying
Description: A 12,5% of body weight backpack will be used for each measurement. Lung function will be assessed while carrying a double strap backpack, a mono shoulder backpack and without a backpack.
Study NCT02700282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Backpack Carrying
Description: A 12,5% of body weight backpack will be used for each measurement. Lung function will be assessed while carrying a double strap backpack, a mono shoulder backpack and without a backpack.
Study NCT04589923 — intervention group
Intervention type: DEVICE
Intervention: Lifelight® Data Collect Blood Pressure Group
Description: The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
Study NCT04589923 — intervention group
Intervention type: DEVICE
Intervention: Lifelight® Data Collect Oxygen Saturation Group
Description: The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
Study NCT01495767 — intervention group
Intervention type: OTHER
Intervention: Filling in a psychometric questionnaire
Description: Juvenile patients attending the uveitis are asked to fill in a psychometric questionnaire
Study NCT01621217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Will be given weekly intravenously during study treatment.
Study NCT01621217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Will be given intravenously twice together with 5-Fluoruracil during study treatment.
Study NCT01621217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoruracil
Description: Will be given intravenously twice together with Mitomycin C during study treatment
Study NCT01621217 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.
Study NCT02289131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Brushing Protocol
Description: A 2-minute tooth brushing protocol, followed by a mouthwash rinse and application of moisturizer for a total of approximately 15 minutes.
Study NCT01415791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI176,334-1
Description: Subject will receive single dose of ICI176,334-1
Study NCT03813329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modified Sodium Bicarbonate
Description: 4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
Study NCT03813329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified Sodium Bicarbonate
Description: 4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
Study NCT03813329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Modified Sodium Bicarbonate
Description: 4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
Study NCT03813329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acute Sodium Bicarbonate
Description: 3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)
Study NCT03813329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute Sodium Bicarbonate
Description: 3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)
Study NCT03813329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acute Sodium Bicarbonate
Description: 3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)
Study NCT03813329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate (placebo)
Description: 4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate
Study NCT03813329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (placebo)
Description: 4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate
Study NCT03813329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate (placebo)
Description: 4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate
Study NCT02501304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReVENT Sleep Apnea System
Description: The ReVENT Sleep Apnea System consists of minimally invasive biocompatible devices that are placed into the tongue base and palate of patients with obstructive sleep apnea
Study NCT03647501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interbody cage (titanium)
Description: Subject will be implanted with a 3D-printed titanium cage during their lumbar interbody fusion surgery.
Study NCT03647501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interbody cage (PEEK)
Description: Subject will be implanted with a poly-ether-ether-ketone (PEEK) cage during their lumbar interbody fusion surgery.
Study NCT02567435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Given IV
Study NCT04889833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypnosis therapy
Description: Pre-recorded hypnosis therapy audio recording with accompanying visual of a calm ocean to be played at least once daily for 7 preoperative days, the day of surgery, and for 7 days postoperatively.
Study NCT01026883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: A venous blood sample will be taken (15 ml). Blood will be collected in 5 tubes. To avoid hematocrit variations due to the blood draw procedure, the first tube will be discarded. After that, the tourniquet which is used for venipuncture will be removed and 4 EDTA tubes (each 3 ml) will be filled with blood for hematocrit determination, one tube will be sent to the Department of Laboratory Medicine, and the other ones will be processed at the Department of Clinical Pharmacology.
Study NCT01714219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior reconstruction
Study NCT02079805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan tablets
Study NCT02079805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Telmisartan tablets
Study NCT00513669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEV 301& 302 in virosomes
Description: PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90
Study NCT00513669 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inflexal V (active comparator)
Description: Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
Study NCT01891123 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PK guided arm
Description: the dose of PTX or DOC will adjust based on the plasma drug concentration of previous cycle
Study NCT01891123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTX 175mg/m2, DOC 75mg/m2
Description: patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2
Study NCT01636882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVA21
Study NCT04099069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthesia
Description: patient was insert trachial intubation or rigid bronchoscopy with ventilation under general anesthesia
Study NCT04099069 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: anesthesia
Description: patient was insert trachial intubation or rigid bronchoscopy with ventilation under general anesthesia
Study NCT04546087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound scan of the cricothyroid membrane
Study NCT04821596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological collection
Description: Six 5 mL heparinized tubes, approximately 24 mL of blood will be collected as per standard practice. The 5 tubes collected from a given individual will be transported directly to the laboratory. In the laboratory, peripheral blood mononuclear cells (PBMC) will be prepared for the various analyses.~However, in order to minimize the effect of agents other than CoA in MS patients, it is necessary that peripheral blood mononuclear cells are collected before treatment is given: for RR MS patients treated with first-line drugs (IFNβ, glatiramer acetate, teriflunomide and dimethyl fumarate, ...), RR MS patients treated with second-line drugs (natalizumab and fingolimod, ...) and RR MS patients treated with third-line drugs (alemtuzumab, ...).
Study NCT05034003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia crown
Description: Esthetic crowns for capping primary incisor with caries
Study NCT05034003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: composite strip crown
Description: Esthetic resin restoration for primary incisor with caries
Study NCT02368353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Study NCT02368353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive therapy
Study NCT00428454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus-eluting stent, zotarolimus-eluting stent
Description: PCI in chronically occluded coronary artery
Study NCT00428454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sirolimus-eluting stent, zotarolimus-eluting stent
Description: PCI in chronically occluded coronary artery
Study NCT04082065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: hot pack for 15 minutes Myofacial release (10 minutes) and Stretching of hamstrings and Piriformis (5 reps each with 2 second hold)
Study NCT04082065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cyriax lumber manipulation group
Description: Hot Pack, Myofacial Release, stretching of hamstrings and Piriformis (five reps each with 2 seconds hold) and Cyriax Lumbar Manipulation Techniques
Study NCT03812796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domatinostat
Description: Domatinostat is an oral tablet which will be given at a variable dose during the Phase IIA safety run in phase of the trial.~During the Phase IIB efficacy phase of the trial patients will be treated with domatinostat at the safe and tolerated combination dose identified during the Phase IIA safety run in phase.
Study NCT03812796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 10mg/kg every two weeks on the first day of a two week cycle. (Day 1 q 14d) from Cycle 2 onwards.
Study NCT01155544 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Preventing recurrence of substance use.
Study NCT01155544 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Intervention
Description: Preventing recurrence of substance use.
Study NCT00604981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Description: MST is an intensive, family centered, community based treatment originally designed for use with adolescents presenting with serious mental health problems. In this study, MST interventions are aimed at increasing adolescent and family adherence to dietary and exercise recommendations and targeting barriers within the family system, and the broader community systems within which the family is embedded (peers, schools, health care). Decreasing caloric consumption consistent with recommended intake targets, increasing daily exercise and decreasing sedentary activity, are treatment focuses depending on whether the adolescent has difficulty with this aspect of weight management or not.
Study NCT00604981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shapedown
Description: Shapedown, is a clinic-based, adolescent weight loss intervention. Shapedown utilizes psycho educational, behavior, and family therapy techniques in a 10-week group intervention. In order to match MST's length of intervention (6 months), three follow-up sessions are added at monthly intervals.
Study NCT01026974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB
Study NCT01026974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Study NCT03564379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: 25 mg JNJ-42165279 tablet will be administered orally.
Study NCT03564379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet will be administered orally.
Study NCT02412930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Paravertebral Block
Description: paravertebral block was performed by ultrasound guidance at T11, T12 and L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. The injection site was covered with sterile drapes, after cleaning with 10% povidone-iodine solution.~After, patients in both groups were performed patient controlled analgesia (PCA). The PCA was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
Study NCT02412930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group Tramadol
Description: Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
Study NCT02412930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group Tramadol
Description: Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
Study NCT02412930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT02412930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study NCT01944501 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: TMS over the left temporoparietal cortex
Study NCT01944501 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: TMS over the left temporoparietal cortex
Study NCT01944501 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: TDCS over the left temporoparietal cortex
Study NCT01944501 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: TDCS over the left temporoparietal cortex
Study NCT01278329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India)
Description: Approximate playing time = 50 minutes. Mothers advised to listen to it once every day.